Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Average rating

Display 15 Products per page

Market Spotlight: Dry Eye Disease

$1,318.00

This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
November 3, 2022
Find out more
Biomedtracker / Meddevicetracker Q2 2021 Outlook Report

$4,750.00

In this report, we cover catalysts from 28 drugs, devices, diagnostics, and deals expected to occur in early 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.
April 1, 2021
Find out more
Schizophrenia and Bipolar Disorder Payer Interview – US, South

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.
April 28, 2021
Find out more
Schizophrenia and Bipolar Disorder KOL Interview – US, Southeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.
April 28, 2021
Find out more
Schizophrenia and Bipolar Disorder KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.
April 28, 2021
Find out more
Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.
April 28, 2021
Find out more
Schizophrenia and Bipolar Disorder KOL Interview – Germany

$599.00

This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.
April 28, 2021
Find out more
Respiratory Care: Mechanical Ventilators and Pulmonary Function Testing Systems

$4,750.00

Asthma and COPD affect an estimated 590 million people worldwide, with an additional 114 million affected by COVID-19 from March 2020 to March 2021. Devices used in the diagnosis and treatment of these and other respiratory disorders include mechanical ventilators and pulmonary function testing systems.
March 30, 2021
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include the CAR-T therapy Breyanzi, reversible BTK inhibitors MK-1026 and pirtobrutinib, and the PI3K inhibitor TG-1303.
October 1, 2020
Find out more
Diabetes Management: Blood Glucose Monitoring Devices Market (2022)

$4,750.00

The number of people with diabetes worldwide grew from an estimated 180 million in 1980 to approximately 537 million in 2021, and is expected to increase to 783 million by 2045. In 2021, global sales of blood glucose monitoring devices totaled more than $11m. Market drivers include the increasing elderly population and its associated increase in diabetes prevalence, technological developments leading to improved accuracy and integration with wireless apps, increased remote use of continuous glucose meters (CGMs) during the COVID-19 pandemic, expanded sales of CGMs to the larger population of people with type 2 diabetes, and technological simplicity compared to many medical devices (reducing the need for extensive training or medical infrastructure).
December 15, 2022
Find out more
Arthroscopy Products and Sports Medicine Fixation Implants (2021)

$4,750.00

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft tissue fixation implants for the US, five major EU markets, Japan, and the rest of the world.
March 18, 2021
Find out more
Depression KOL Interview – US #2

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.
March 2, 2021
Find out more
Depression KOL Interview – US #1

$599.00

A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.
March 2, 2021
Find out more
Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.
March 1, 2021
Find out more
Inflammatory Bowel Disease (IBD) KOL Interview – US

$599.00

A US gastroenterology expert dives into the treatment algorithm, critical unmet needs, and pipeline drugs for IBD, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.
March 1, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *